Isomorphic Labs 募集600万澳元, 以推进AI药物设计, 并拓展其药物候选者。 Isomorphic Labs raises $600M to advance AI drug design and expand its drug candidates.

人工智能驱动的药物设计公司 Isomorphic Labs 筹集了 6 亿美元的资金，由 Thrive Capital 领投，GV 和 Alphabet 也进行了投资。 Isomorphic Labs, an AI-driven drug design company, has raised $600 million in funding, led by Thrive Capital, with GV and Alphabet also investing. 这些资金将用于推广其AI药物设计技术,并扩大药物候选者的渠道。 The funds will be used to advance its AI drug design technology and expand its pipeline of drug candidates. 该公司旨在利用最先进的人工智能模型加速药物发现,并开发各种疾病的治疗方法。 The company aims to accelerate drug discovery and develop treatments across various diseases using its cutting-edge AI models.